Viatris Faces Nashik Supply Test As Street Sits Near Low End Of Raised Outlook

Three months ago Viatris finally did something it had avoided for several quarters: it raised its full-year outlook across revenue, adjusted EBITDA and adjusted EPS, rather than simply reaffirming it. Management also warned that the third quarter would absorb the worst of a new supply problem tied to its Nashik facility in India. The November 5 report, due before the opening bell, is the first real look at whether the raise can hold up once that headwind lands.

The Street expects adjusted earnings of $0.64 a share on revenue of about $3.78 billion. That would be a 4.5% earnings decline from the year-ago $0.67 on essentially flat sales, and a step down from the $0.69 posted last quarter. The softer comparison is largely by design. Management said second-half EBITDA and EPS would come in slightly below the first half, a reversal from earlier calls that had pointed to a back-half-weighted year. The Earnings Whisper sits at $0.70, roughly six cents above consensus. That is a meaningful gap, and it suggests the informal bar is closer to a repeat of last quarter than to the dip analysts have modeled.

The full-year math points the same way. Viatris now guides to $2.45 to $2.59 a share on revenue of $14.55 billion to $14.95 billion. Consensus of $2.46 is barely above the bottom of the EPS range, while the $14.74 billion revenue estimate sits right at the midpoint. Analysts are accepting management's sales outlook but doubting much of the earnings upside. That leaves room for a positive surprise if cost savings keep running ahead of plan. Management said its strategic review targets $650 million in gross savings over three years and is on or ahead of schedule. It also noted that first-half EBITDA growth was roughly double the revenue beat. If that pattern continues while revenue absorbs the Nashik hit, the low-end positioning of estimates may prove too cautious.

The Nashik disruption is the main swing factor. Management sized it at $100 million to $150 million of second-half revenue, concentrated in low-margin oral solid generics in emerging markets and Europe, and expected the third quarter to bear the larger share. A hit near the low end of that range, with margins holding up, would support the idea that the damage is mostly to revenue rather than profit. Any sign that the problem is spreading, that FDA discussions are dragging on, or that fourth-quarter relief is slipping would undercut the case. Greater China is the second test. Its growth outlook moved up from 3% to low double digits over three calls, but a hospital-channel procurement change was expected to slow second-half growth, with province-level clarity promised by November. Investors should also look for updates on estradiol patch supply, where only about 70% of orders were being filled, and on pressure facing Breyna and Yupelri in North America.

Expectations have warmed considerably. Bullish sentiment has roughly doubled from the prior quarter, and the stock has gained 3.1% since the last report while the S&P 500 was flat. At $18.72, shares sit well above their 200-day moving average of $15.79 and within a hair of the post-earnings high of $18.83, already clearing last quarter's peak. A stock testing a breakout ahead of a quarter guided to be weaker leaves less room for a messy report.

In the end, the question is whether the guidance raise was durable or front-loaded. If Viatris can contain Nashik within its stated range, keep China growing through the policy change and keep cost savings outpacing revenue, the low-end consensus looks conservative. If the supply hit grows or China stalls, the first raise of the cycle could start to look like the high point.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.